Update on Asthma–COPD Overlap (ACO): A Narrative Review

Abstract

Although chronic obstructive pulmonary disease (COPD) and asthma are well-characterized diseases, they can coexist in a given patient. The term asthma–COPD overlap (ACO) was introduced to describe patients that have clinical features of both diseases and may represent around 25% of COPD patients and around 20% of asthma patients. Despite the increasing interest in ACO, there are still substantial controversies regarding its definition and its position within clinical guidelines for patients with obstructive lung disease. In general, most definitions indicate that ACO patients must present with non-reversible airflow limitation, significant exposure to smoking or other noxious particles or gases, together with features of asthma. In patients with a primary diagnosis of COPD, the identification of ACO has therapeutic implication because the asthmatic component should be treated with inhaled corticosteroids and some studies suggest that the most severe patients may respond to biological agents indicated for severe asthma. This manuscript aims to summarize the current state-of-the-art of ACO. The definitions, prevalence, and clinical manifestations will be reviewed and some innovative aspects, such as genetics, epigenetics, and biomarkers will be addressed. Lastly, the management and prognosis will be outlined as well as the position of ACO in the COPD and asthma guidelines.

Introduction

Although chronic obstructive pulmonary disease (COPD) and asthma are distinct entities, they can coexist in a given patient. The term asthma–COPD overlap (ACO) was introduced to describe these patients. In some patients, the overlap appears obvious, such as COPD patients who demonstrate a particular phenotype that is characterized by a predominant type 2 (T2) inflammation, and manifest clinical characteristics associated with asthma, such as significant reversibility and increased number of eosinophils in peripheral blood and the airways, while in others, the clinical expression of the overlap is more subtle.¹ ACO may represent between 10% and 40% of COPD patients and between 15% and 35% of asthma patients.²

The concept of overlap between COPD and asthma is not new and dates back to 1961 with Orie’s “Dutch hypothesis”,³ which acknowledged the coexistence of biological, physiological and clinical characteristics of asthma and COPD in some patients. In 2007, the Canadian COPD guidelines adopted tailored management in patients who expressed features of both asthma and COPD,⁴ and two years later Gibson and Simpson named this condition an overlap syndrome.⁵ In 2014, the Global Initiative for Asthma (GINA) and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) published a joint document on a “asthma COPD overlap syndrome (ACOS)”, which was defined as the presence of persistent airflow limitation with several features usually associated with asthma and several features usually associated with COPD.⁶ The next step was to remove the word “syndrome” from ACOS to become “ACO” since it was considered to have several different clinical manifestations, which did not fulfil all the criteria of a syndrome.⁷

Since the publication of the GINA-GOLD document in 2014, there has been a growing interest in research in ACO, with the number of articles included in PubMed increasing from 91 in 2014 to 502 by the end of 2020. Despite this increase in the interest in ACO, there are still some controversial issues around this concept. Among them, there is no universally accepted definition, and GOLD 2020 for the first time no longer refers to ACO; instead, it emphasizes that asthma and COPD are different disorders, although they may share some common traits and clinical features (eg, elevated blood eosinophil count, partial reversibility), and they could also coexist in an individual patient.⁸ In this context, it is relevant to summarize the current knowledge about the different aspects of ACO, which may help to better define it and establish the best therapeutic strategies for patients suffering from this condition.

This manuscript summarizes the current state-of-the-art of ACO. The definitions, prevalence, and clinical manifestations will be reviewed and innovative aspects such as genetics, epigenetics, and biomarkers will be addressed. Lastly, the prognosis and management will be outlined as well as the position of ACO in the COPD guidelines.

Definition of ACO

During the last decade, there have been several definitions of ACO. Most of these definitions recognize that there are individuals with smoking-related COPD on a background of T2 inflammation expressed as increased eosinophil counts in sputum and/or peripheral blood, and/or significant reversibility of airflow to short-acting β2-agonists.^1,9,10 These patients could be defined as a particular phenotype of COPD called ACO because of their resemblance to asthma, COPD with features of T2 inflammation or eosinophilic COPD.¹¹ Other subjects suffering from asthma with significant exposure to smoking may lead to the development of some unique characteristics of COPD, ie not fully reversible airflow obstruction, reduction in diffusing capacity of the lungs for carbon monoxide (DLCO), and emphysema on computed tomography scans. These individuals could also be considered to have ACO.^11–13 It is important to highlight that significant smoking (or other noxious) exposure is necessary for the diagnosis of COPD, and therefore, of ACO. Otherwise, non-fully reversible airflow limitation in an asthmatic patient in the absence of significant smoking exposure should be diagnosed with chronic, irreversible asthma but not ACO.^12,14

The heterogeneity of individuals included in the definition of ACO led to the development of many consensus definitions many including key features, namely, non-fully reversible airflow obstruction, significant exposure to smoking or other noxious irritants, plus an asthmatic component defined as previous or current diagnosis of asthma, elevated blood and/or sputum eosinophils or some degree of airflow reversibility.^6,15,16

The agreement on a consensus definition is crucial to enable comparison of data obtained across different studies around the world. In this respect, the most widely recognized definition of ACO is that of the joint GINA/GOLD document published in 2014.⁶ The first step in the approach to these patients is the identification of a chronic airway disease based on history, ie, chronic or recurrent cough, sputum production, wheezing, or repeated acute lower respiratory tract infections. In the second step, the features of asthma and those of COPD that best describe the patient (ie, age at onset, pattern of symptoms, results of pulmonary function tests, and findings on chest imaging) must be identified, which in turn, results in a diagnosis of COPD, asthma or ACO, according to the presence of signs and symptoms predominantly of either COPD, asthma or both. In the third step, spirometry is recommended for assessing the obstructive pattern at the initial or a subsequent clinic visit.

In 2016, a global expert panel discussion, comprised of various specialists from North America, Western Europe and Asia, reported a consensus on ACO based on major and minor clinical, spirometric and laboratory criteria (Table 1).¹⁵ In this report, the authors advocated that patients who meet all three major criteria and at least one minor criterion be considered for the diagnosis of ACO. Because airway reversibility and peripheral blood eosinophil counts were included, this definition would be more quantitative and objective, and easier to implement in daily clinical practice.

Table 1.

Criteria for Diagnosis of Asthma–Chronic Obstructive Pulmonary Disease Overlap Syndrome

Major

1. Persistent airflow limitation [post-bronchodilator FEV1/FVC <0.70 or LLN] in individuals 40 years of age or older; LLN is preferred. 2. At least 10 pack-years of tobacco smoking OR equivalent indoor or outdoor air pollution exposure [eg biomass] 3. Documented history of asthma before 40 years of age OR BDR of >400 mL in FEV1

Minor

1. Documented history of atopy or allergic rhinitis 2. BDR of FEV1 ≥200 mL and 12% from baseline values on 2 or more visits 3. Peripheral blood eosinophil count of ≥ 300 cells/μL

Notes: The committee recommends the presence of all three major criteria and at least one minor criterion for asthma-chronic obstructive pulmonary disease overlap syndrome. FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; BDR, bronchodilator response using 400 mg of albuterol/salbutamol [or equivalent]; LLN, Lower limit of normal. Reproduced with permission of the © ERS 2021: European Respiratory Journal 48 (3) 664–673; DOI: 10.1183/13993003.00436-2016 Published 31 August 2016. Reproduced from: Sin DD, Miravitlles M, Mannino DM, et al. What is asthma-COPD overlap syndrome (ACOS)? Towards a consensus definition from a roundtable discussion. Eur Respir J. 2016;48: 664–673.¹⁵ Copyright © ERS 2016.

Other objective and quantifiable traits of COPD and asthma may be of help in identifying subjects with ACO. Computed tomography (CT, a multi-detector chest CT scanning with deep breath holding in the supine position) of the chest and the pulmonary diffusion capacity of carbon monoxide (DLCO) provide information about gas exchange units (ie alveoli), which may be useful for identifying features of COPD. Fractional exhaled nitric oxide (FeNO), a reliable marker of airway inflammation in asthma, is considered to be a promising diagnostic tool for ACO.^17,18 In countries such as Japan, where CT is widely used and FeNO measuring devices are clinically applied in more than 2000 facilities, the preferred ACO diagnostic criteria are those that emphasize objective indicators including CT imaging, DLCO and FeNO as shown in Table 2.^19,20 Due to the differences in medical resources, country-specific adaptations of the global definition may be required.

Table 2.

Definition of ACO from Japanese Respiratory Society

Basic Characteristics

Post-bronchodilator FEV1/FVC < 70% in individuals 40 years of age or older

Features of COPD

(1 item out of 1–3)

1. Smoking history (> 10 pack-year) or similar air pollution exposure

2. Presence of low attenuation area showing emphysematous lesions on CT

3. Impaired pulmonary diffusion (DLCO and/or DLCO/VA <0.8)

Features of asthma

(2 items out of 1–3 or 1 item out of 1–3 and 2 items out of 4)

1. Variable (diurnal, day to day, seasonal) or paroxysmal respiratory symptoms (cough, sputum, dyspnea)

2. Asthma diagnosis history under 40 years

3. Exhaled nitric oxide > 35ppb

4-1) Complication of allergic rhinitis

2) Bronchodilator response of FEV1≥200 mL and 12% from baseline

3) Peripheral blood eosinophil count> 5% or 300 cells/μL

4) High IgE (for total or inhaled antigens)

Notes: If basic characteristics, features of asthma and features of COPD are satisfied, diagnose as ACO. Reproduced from Yanagisawa S, Ichinose M. Definition and diagnosis of asthma-COPD overlap (ACO). Allergol Int. 2018;67(2):172–178.²⁰ Copyright © 2018 Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved. Creative Commons (CC BY-NC-ND 4.0; https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode).

In summary, the first step in diagnosing ACO is to confirm a diagnosis of COPD based on smoking (or equivalent noxious exposure) history, respiratory symptoms and presence of non-fully reversible airflow obstruction. Subsequently, the diagnosis of asthma should be confirmed by a well-documented history of asthma and/or a current diagnosis of asthma according to guidelines.²¹ If the diagnosis of asthma cannot be established, the diagnosis of ACO could be suggested by asthmatic traits, such as the presence of sputum or blood eosinophils ≥300 cells/µL.¹⁶

Epidemiology of ACO

Both asthma and COPD are common diseases in adults. However, the prevalence of ACO is not well established.

The first observation is that the prevalence of ACO in patients with COPD varies widely according to the study design and definition used (Table 3). Population-based studies enrol a large number of individuals without the bias of predefined inclusion and exclusion criteria. However, due to the lack of data on reliable pulmonary function or other diagnostic tests, many population-based studies relied on a physician diagnosis or diagnostic codes only. Some of these studies may have overestimated the prevalence of ACO, as in a survey based on data from the Korean National Health Insurance Database in which 54% of the 185,147 patients identified with COPD also had a diagnostic code for asthma.²² To overcome this problem, some population-based studies included standardised spirometry, but the number of participants was significantly reduced. As an example, Krishnan et al²³ performed a study on 2165 adults with spirometry and a diagnosis of airways disease from the Optimum Patient Care Research Database (UK primary care database). They found a prevalence of ACO of 20.5% among patients with a diagnosis of COPD, 14% among those diagnosed with asthma and 32% among those with both clinical diagnoses of asthma and COPD. These results suggested that only one-third of patients with diagnostic codes for asthma and COPD have objective characteristics of ACO. Similar results have been found in other countries. A Spanish population-based study using post-bronchodilator spirometry found a prevalence of ACO of 17.4% among individuals with COPD.²⁴ In an Italian study, the prevalence of ACO among COPD was 32.7% in subjects aged 20 to 44 years, 26.9% in those aged 45 to 64 years and 25.3% in ages 65–84 years. The same study found a prevalence of ACO in the general Italian population of 1.6% (age 20–44), 2.1% (age 45–64), and 4.5% (age 65–84).²⁵

Table 3.

Prevalence of ACO in Patients with COPD

	Country	No. of ACO	Prevalence of ACO in Patients with COPD	ACO Definition
Population studies
Marsh et al (2008)125	New Zealand	53	55.2%	Post BD FEV1/FVC <0.7 AND BDR ≥15% or peak flow variability ≥20% or physician diagnosis with current symptoms or inhaler use
de Marco et al (2013)25	Italy		Age 20–44: 32.7%	Self-reported physician diagnosis of asthma and COPD
			Age 45–64: 26.9%
			Age 65–84: 25.3%
Miravitlles et al (2013)24	Spain	67	17.4%	Post BD FEV1/FVC <0.7 AND Self-reported physician diagnosis of asthma
Rhee et al (2014)22	South Korea	101,004	54.6%	ICD-10 code of asthma and COPD AND Use of asthma and COPD medication
van Boven et al (2016)69	Spain	5093	18.3%	Physician confirmed diagnosis (ICD-9 code) of asthma and COPD
Krishnan et al (2019)23	UK	335	Patients with physician diagnosis of COPD only: 20.5% Patients with physician diagnosis of both asthma and COPD: 32.1%	Age ≥40 years AND Current or former smoking AND Post BD FEV1/FVC <0.7 AND BDR ≥12% and 200 mL
Morgan et al (2019)126	Low- and middle-income countries	450	Peru: 13.6%, Argentina: 29.3%, Chile: 32.5%, Uruguay: 35.1%, Bangladesh: 34.9%, Uganda: 21.3%	COPD: post BD FEV1/FVC <LLN AND Asthma: fulfilling 1 of 3 criteria - (1) Self-report of wheezing in 1 year, (2) Self-report of medication use for asthma in 1 year, (3) Self-report of a physician diagnosis of asthma
COPD cohort studies
Jo et al (2020)26	South Korea	264	Specialists’ diagnosis: 24.8%	Post BD FEV1/FVC <0.7 AND Pulmonologist/allergist diagnosis of asthma
		32	ATS roundtable criteria: 3.0%	All 3 major and at least 1 minor Major: (1) Post BD FEV1/FVC <0.7 and age ≥40, (2) Smoking ≥10 p-y or exposure to air pollution ≥10 year, (3) History of asthma before age 40 or BDR >400 mL in FEV1 Minor: (1) History of atopy or allergic rhinitis, (2) Separate BDR ≥12% and 200 mL, (3) Blood eosinophil count ≥300 cells/μL
		138	GINA/GOLD document: 12.9%	Patients who met at least 3 items in both the asthma and COPD categories
		171	Modified Spanish criteria: 16.0%	Post BD FEV1/FVC <0.7 AND at least 1 major or 2 minor Major: (1) Previous history of asthma, (2) BDR >15% and 400 mL Minor: (1) IgE >100 IU or history of atopy, (2) BDR >12% and 200 mL, (3) Blood eosinophil >5%
		138	Updated Spanish criteria: 12.9%	((1) and (2)) OR ((1) and (3)) (1) Age ≥35, smoking ≥10 pyrs, and post BD FEV1/FVC <0.7 (2) Current diagnosis of asthma (3) BDR ≥15% and 400 mL, and/or blood eosinophil ≥300 cells/μL
Barrecheguren et al (2020)10	Canada	264	Any ACO: 50.6%	Post BD FEV1/FVC <0.7 AND One of the following asthma features
		105	Reversibility: 20.1%	Post BD FEV1/FVC <0.7 AND BDR ≥12% and 200 mL
		31	Large reversibility: 5.9%	Post BD FEV1/FVC <0.7 AND BDR ≥15% and 400 mL
		124	Atopy: 23.8%	Post BD FEV1/FVC <0.7 AND Self-reported presence of respiratory allergies or hay fever
		162	Physician diagnosis: 31.0%	Post BD FEV1/FVC <0.7 AND Self-reported physician diagnosis of asthma
		27	Reversibility + atopy: 5.2%
		80	Atopy + physician diagnosis: 15.3%
		20	Reversibility + atopy + physician diagnosis: 3.8%

Abbreviations: No., number; ACO, asthma COPD overlap; BD, bronchodilator; ICD, international classification of diseases; LLN, lower limit of normal; ATS, American Thoracic Society; p-y, pack-years; BDR, bronchodilator response; GINA, Global Initiative for Asthma; GOLD, Global Initiative for Chronic Obstructive Lung Disease; IgE, immunoglobulin E.

In cohort studies, the prevalence of ACO can be measured more accurately than in population-based study, since data such as spirometry with bronchodilator reversibility and asthma features such as blood eosinophil counts, IgE, and atopy, which are usually not fully available in population-based studies, may be available in cohort studies. However, cohort studies may not be representative of airway diseases in the general population because patients are usually enrolled in referral (or tertiary) hospitals. The prevalence of ACO among COPD patients in cohort studies is significantly lower than in population-based studies, but varies widely depending on the definition used.^9,10,13 Jo et al²⁶ found a prevalence of ACO according to various well-known definitions of between 3% and 24.7% among 1067 COPD patients from the KOCOSS cohort. Using CanCOLD data, Barrecheguren et al¹⁰ found a prevalence of ACO among COPD patients ranging from 3.8% to 50.6% according to seven different ACO criteria.

Prevalence of ACO has also been reported in patients with asthma. Milanese et al²⁷ performed a survey on asthma patients aged ≥65 and found a prevalence of ACO of 29% using the GINA-GOLD ACO definition. Forty-three percent of ACO patients were smokers or former smokers and interestingly 84% reported chronic bronchitis and 35% demonstrated impaired DLCO. Kiljander et al²⁸ investigated primary care asthma patients with a smoking history of at least 10 pack-years and found that 27.4% of these patients demonstrated irreversible airflow limitation and were diagnosed with ACO. This prevalence increased up to 37.8% in a population of 256 asthma patients from a tertiary referral hospital.

Recently, Hosseini et al²⁹ performed a meta-analysis of 27 studies, which included population-based and cohort studies, in order to estimate the prevalence of ACO. Their results showed a prevalence of 2.0% (95% confidence interval (CI) 1.4–2.6%) among the general population, 26.5% (95% CI 19.5–33.6%) among asthma patients and 29.6% (95% CI 19.3–39.9%) among COPD patients, but with substantial heterogeneity between studies.

In summary, the prevalence of ACO obtained from population-based studies can only be considered as indicative due to the lack of specific tests to reliably diagnose asthma features in patients with COPD. Although the prevalence of ACO in cohort studies may vary significantly according to the definition used and the methodology used to enrol participants, the most widely used definitions provide estimates of the prevalence of ACO of around 20% to 30%, similarly among patients with COPD or asthma.

Clinical Manifestations of ACO

Studies that have reported on the clinical manifestations of ACO have focused on symptoms (most notably dyspnea), health-related quality of life, lung function, exercise intolerance, and exacerbations which are considered most relevant to patients and to physicians.

Most studies reported that ACO results in more severe symptoms than asthma or COPD alone, including a recent study that observed a higher disease burden for eosinophilic ACO compared with eosinophilic COPD or asthma.³⁰ However, several individual trials and a systematic review suggested that this affirmation should be nuanced.³¹ Indeed, looking at each manifestation individually provides a better overview of the impact of ACO on patients. In terms of symptoms, it appears that patients with ACO experience more wheezing and mucus production than patients with asthma or COPD.^32,33 Higher Medical Research Council (MRC) scores suggest that ACO patients also have more dyspnea^24,25,27 with the three populations: asthma, COPD and ACO, otherwise being quite similar regarding symptoms.

Studies assessing lung function have mostly reported on FEV1 and FEV1 decline. Most of them show a lower FEV1 in ACO patients than in asthmatics, although similar values to that of COPD patients are found.^{27,32,34–36} Regarding lung function decline, some small studies have not observed significant differences in the rate of decline of FEV1 between the asthma, COPD and ACO groups.^32,33 However, a small Korean cohort study showed a slower decline of FEV1 for ACO compared to COPD over almost 6 years of follow-up (13.9 mL/year versus 29.3 mL/year; p=0.04).³⁷ Similar results were reported by Lange et al³⁸ using data from the Copenhagen City Heart Study with an FEV1 decline of 39.5 mL/year in COPD, compared with 27.3 mL/year in ACO patients with early onset asthma. However, patients with ACO based on late onset asthma had the worst prognosis with a decline of 49.6 mL/year (p=0.003).³⁸ Though rarely investigated, DLCO appears similar in ACO and COPD patients, but is significantly reduced compared to asthmatic patients.^12,14,39,40 Patients with ACO may have marked air trapping indicated by a higher residual volume compared to patients with asthma or COPD.^10,39 Surprisingly, exercise capacity, which has been assessed using various methodologies in individual studies, does not appear to be significantly worse in patients with ACO than in those with asthma or COPD.^35,41

Regarding exacerbations, a systematic review of eleven studies showed a significantly higher rate of exacerbations in ACO compared to asthma or COPD.³¹ A large epidemiological study in the US showed more hospitalisations and emergency department visits for ACO patients compared to COPD patients.⁴² Similarly, two large epidemiological studies in Spain and Latin America showed a significantly higher frequency of exacerbations in ACO compared to COPD patients.^24,43 The Copenhagen City Heart Study demonstrated a significantly higher risk of severe exacerbations in ACO patients, especially in those associated with late onset asthma, compared with asthma or COPD alone.³⁸ Finally, a Japanese study did not find poor clinical outcomes in patients with ACO receiving appropriate treatment.⁴⁴

Clinical differences between ACO, asthma and COPD were more evident in the initial description of ACO cohorts compared with the more recent studies.^22,45,46 Again, this difference may be due to differences in ACO definitions and methodology of the studies.^9,10,47 The selection of asthma and COPD populations to which ACO is compared can also account for disparities amongst studies. Lastly, like asthma and COPD, ACO is a heterogenous entity, whose clinical manifestations are expected to vary from one study to another.^12,14,48 Refinement in the understanding of ACO and its underlying mechanisms will enable better appreciation of its differential clinical manifestations.

In conclusion, despite the differences in diagnostic criteria for ACO, the majority of studies have reported a high symptom burden associated with ACO, with a significantly higher frequency and severity of exacerbations compared with asthma and COPD.

Genetics and Epigenetics of ACO

Although the underlying genetic architecture of ACO remains largely a mystery, there are some emerging data to indicate the existence of specific chromosomal loci that may be responsible for this phenotype. The strongest evidence to date comes from the COPDGene study, which examined the genetic epidemiology of ~10,000 men and women 45 to 80 years of age, who had at least a 10 pack-year history of smoking.⁴¹ The subjects in the study were genotyped on the Illumina Human Omni Express array (Illumina, San Diego, CA, USA) with imputation based on the 1000 Genomes Phase I v3 European reference panel for the non-Hispanic whites and cosmopolitan reference panels for African–Americans. This approach included over 6 million single nucleotide polymorphisms (SNPs) for the analysis. Of the 3570 subjects with GOLD 2 or greater severity of COPD (ie post-bronchodilator FEV1 ≤80% of predicted) in the COPDGene study, approximately 13% (N=450) had ACO, as defined by GOLD 2 or greater severity of COPD and a physician diagnosis of asthma before the age of 40. The SNP that was most strongly related to ACO was within the CSMD1 gene on chromosome 8 (rs1179254; p=1.57 x 10⁻⁶) in non-Hispanic whites; whereas in the African-American population, it was rs2686829 (which is found on chromosome 7). If the ethnic groups were combined, many top hits were located on chromosome 14 near or within the gene GPR65. Other SNPs are shown in Table 4. Although the precise role of this protein is unknown in ACO, GPR65 is a member of the G protein-coupled receptor family and is expressed in activated eosinophils. Genetic knock-out of GPR65 has been shown to reduce levels of eosinophils in murine models of asthma. It should be noted, however, that none of the SNPs in the non-Hispanic whites, African-Americans or the meta-analysis, met the genomic significance threshold of p <10⁻⁸. Interestingly, none of the known asthma SNPs or COPD SNPs were significantly enriched in the ACO population (Table 4).

Table 4.

Different Single Nucleotide Polymorphisms (SNPs) Identified in Patients with ACO

How the “Asthmatic” Phenotype was Defined in the Study	Study	Promising SNPs, Nearest Gene and p-value	Replication in an External Cohort
Physician-diagnosis before age 40 yrs41	COPDGene (non-Hispanic whites)	rs11779254, CSMD1 (10−6)	No
		rs59569785, SOX5 (10−6)
		rs10860172, RMST (10−6)
		rs72812713, SEMA6A (10−6)
		rs4298581, ZDHHC21 (10−6)
Physician-diagnosis before age 40 yrs41	COPDGene (African-Americans)	rs2686829, PKD1L1 (10−7)	No
		rs9577395, ATP11A (10−6)
		rs3864801, REEP3 (10−6)
		rs12681559, NRG1 (10−6)
		rs28895885, AGA (10−6)
		rs115905118, KCNK1 (10−6)
Airway hyper-reactivity49	Lung Health Study (non-Hispanic whites)	rs10491678, LINGO2 (10−6)	No
		rs9486594, PDSS2 (10−6)
		rs7618314, RETNLB (10−6)
		rs2642660, SGCD (10−4)
Inhaled steroid response (FEV1 decline)50	Lung Health Study (non-Hispanic whites)	rs111720447, gene unknown (10−5)	Yes
		rs10057473, NR3C1 (10−2)

Hansel et al⁴⁹ examined another potential definition of ACO by evaluating the genetic architecture of airway hyperresponsiveness of COPD patients in the Lung Health Study (LHS). They genotyped 2814 non-Hispanic whites and related the underlying genetic structure of these participants with their level of airway responsiveness (as measured by a methacholine challenge test) at baseline and then at year 5 of follow-up. Although no SNPs reached the genetic threshold for statistical significance, 4 loci were identified that demonstrated nominal statistical significance (p-value between 10⁻⁴ and 10⁻⁷). None replicated and only 2 of the genes near these SNPs were lung expression quantitative trait loci (SGCD and MYH15).

Another phenotype of ACO is responsiveness to inhaled corticosteroids. This was examined in Lung Health Study-2, which was a randomized controlled trial to evaluate the therapeutic benefits of inhaled corticosteroids (ICS) (triamcinolone 1200 μg/d) on the rate of FEV1 decline over 3 years in approximately 800 patients with COPD. Obeidat et al⁵⁰ did not find any SNPs that reached genome-wide significance. However, there were 2 SNPs that significantly modified the effects of ICS on the rate of FEV1 decline, which were replicated in an external cohort, the Advair Biomarker in COPD trial, which was a short-term randomized controlled trial that evaluated the effects of ICS on lung function in COPD patients.

Together, these data have elucidated promising genetic loci that may play a role in ACO. However, it should be noted that most studies to date have been underpowered to detect SNPs at a genome-wide significance level and replication of genetic “hits” has been lacking except for a few SNPs. Larger studies with improved phenotyping will be required to identify genes that are responsible for ACO.

Biomarkers of ACO

The lack of a strict ACO definition results in the need for biomarkers that could help in the identification of this phenotype. There is an increased awareness of the importance of recognizing ACO by using biomarkers.⁵¹ However, there are no biomarkers that can clearly differentiate ACO from asthma or COPD.⁵²

Inflammation in COPD is predominantly mediated by T-helper cells (Th1), whereas in asthma T-helper cells (Th2) and type 2 innate lymphoid cells (ILC2) are key players in the inflammatory response. Th1 cells enhance cell-mediated immunity and phagocyte-dependent inflammation through the production of interferon (IFN)-γ, interleukin (IL)-2, and tumour necrosis factor (TNF), while Th2 and ILC2s produce IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13, resulting in strong antibody responses and eosinophil accumulation, but inhibition of phagocyte-independent inflammation. The inflammatory pathways activated by both Th2 and ILC2 cells are collectively known as Type 2 inflammation. However, both COPD and asthma are heterogeneous diseases, and the two different inflammatory pathways may overlap in some patients, leading to a mixed inflammatory pattern.

Blood lymphocytes are usually low in ACO but are further reduced in COPD.⁵³ It is suggested that IL-13 could be central to the regulation of inflammation in these conditions.⁵⁴ FeNO, blood eosinophils, and allergen-specific immunoglobulin E (IgE) are proposed for distinguishing between asthma and COPD.⁶ Although the addition of serum IgE does not clearly improve the clinical definition of ACO, it could be used to subdivide individuals with atopic and non-atopic ACO, who might have different biologic mechanisms and potential treatments.⁵⁵ Inflammation in asthma predominantly involves eosinophils, whereas in COPD it is characterized by neutrophils.^5,56 FENO and eosinophils suggest local and systemic eosinophilic inflammation, which is suggestive of asthma,^57,58 as well as markers of atopy such as total serum IgE and antigen-specific IgE levels.⁵⁹ These inflammatory biomarkers could be used to support the diagnosis of ACO in a patient with COPD.⁶⁰ In this respect, the cut-off for high blood eosinophil count in COPD to identify a Type 2 predominant inflammation is still under discussion, but most studies suggest ≥300 cells/μL.⁶¹ Serum periostin is high in patients with ACO as well in those with asthma but not in patients with COPD, whereas serum YKL-40 is high in both patients with ACO and COPD, but not in asthma.⁶² These results suggest that ACO has both pathogeneses of asthma and COPD leading to high expression of periostin (a surrogate marker of IL-13 activity and Type 2 inflammation) and YKL-40 (non-Type 2 inflammation) and combined assessment of serum periostin and YKL-40 could help in the diagnosis of ACO.

The serum levels of IL-9, vascular endothelial growth factor A (VEGFA) and placental growth factor (PIGF) in patients with ACO are significantly higher than in non-ACO asthmatics, while the levels of IL-8 and IL-17A are lower in ACO compared to asthmatics.⁶³

Recently, it was reported that 11 metabolites: serine, threonine, ethanolamine, glucose, cholesterol, 2-palmitoylglycerol, stearic acid, lactic acid, linoleic acid, D-mannose, and succinic acid, were found to be significantly altered in ACO as compared with asthma or COPD.⁶⁴ This provides novel insights into metabolic pathways and inflammatory mediators involved in the mechanisms underlying ACO and how these processes may be linked to each other and also with the pulmonary function impairment. Lastly, there are epigenetic changes showing a characteristic expression profile of miRNAs in ACO, distinctive from asthma and COPD.^65,66

The different inflammatory mechanisms involved in asthma and COPD may overlap in certain patients, but so far, no single biomarker or combination of biomarkers can be used to accurately identify ACO. Blood eosinophils, FeNO and periostin are readily available to identify the T2 inflammation in COPD patients. Recent studies suggest that a set of interleukins could be useful to detect a mixed inflammatory pattern (T2 and non-T2) with a high degree of certainty (Figure 1). It is uncertain, however, whether these new biomarkers may provide better diagnostic accuracy for ACO compared with the traditional T2 biomarkers or if they may play a role in the future for the identification of ACO in clinical practice. Moreover, their reproducibility is uncertain and is yet to be proven or specified, ie some biomarkers like blood eosinophil count may require repeated measures.

Figure 1.

Proposed biomarkers for differentiating ACO from asthma and COPD.

Prognosis of ACO

The long-term outcomes of ACO patients in terms of survival have been explored in both population-based and cohort studies with conflicting results. Most population-based studies have reported increased mortality in patients with ACO, probably due to the defining criteria of the coexistence of both diagnoses, asthma and COPD, that is usually associated with more clinical visits and higher severity. In contrast, most cohort studies show lower mortality in ACO than in COPD, probably due to the better response of these patients to medical treatment compared to COPD alone. Regarding population-based studies, Kumbhare et al⁶⁷ investigated mortality among patients with obstructive lung disease, based on self-reported diagnoses of asthma, COPD and ACO, compared to the US general population. The ACO group was younger and had a higher proportion of ex-smokers than the group with COPD. Mortality rates from cardiovascular disease and malignancy were similar across the disease categories, but ACO patients had a disproportionately higher number of deaths from chronic respiratory disease compared to the other groups, although this was not statistically significant compared to COPD after adjusting for age, sex and smoking status. Similar results were observed by Baarnes et al⁶⁸ in a population of over 57,000 adults aged 50–64 years. ACO (n=662) was defined as at least one hospital admission for asthma and one for COPD at different time points. All-cause mortality was found to be significantly higher among participants with ACO compared to either asthma or COPD alone, especially among women and younger participants. Finally, in a large epidemiological study in Denmark with 8382 participants, patients with ACO associated with late onset asthma had the worst survival with a reduced life expectancy of 12.8 years compared with healthy never-smokers, which was significantly worse than the 10.1 years of reduced survival of COPD and 3.3 years of asthma patients. Patients with ACO associated with early onset asthma had a similar survival compared with COPD (9.3 years reduction in survival).³⁸

In contrast, the cohort studies provide contradictory results in terms of survival for patients classified as ACO. A multicenter, prospective study of 831 patients with obstructive lung disease showed a one-year survival rate of 94.7% for ACO compared with 87.3% for COPD (p<0.05).⁶⁹ Another retrospective, observational study of 891 COPD patients classified according to the Spanish COPD guidelines into ACO, non-exacerbators, exacerbators with chronic bronchitis and exacerbators with emphysema. Golpe et al⁷⁰ found that ACO patients had the best long-term prognosis compared to the three other phenotypes of COPD. However, no significant differences in mortality were found after adjusting for potential confounders, suggesting that the observations were primarily driven by between-group differences in COPD severity and co-morbidities.

A retrospective, 10-year follow-up study of 214 patients hospitalized with an exacerbation of COPD reported that ACO patients had a significantly better survival than patients with COPD alone (mean survival 4.7 vs 1.7 years, p=0.001).⁷¹ Poor lung function was associated with poor survival in both groups, but the prognosis was still significantly better in ACO patients irrespective of whether the FEV1 was over or under of 50% predicted. However, patients with higher BMI (>25) seemed to have a trend for better survival (p = 0.055), but no differences were found between ACO and COPD groups. This “obesity paradox” has been documented before in patients with COPD and appears to be valid also in patients with ACO. Another study evaluated 15-year mortality in 1065 individuals older than 65 years of age in Italy,⁷² and reported a significantly higher risk of death in individuals with ACO compared to controls (Hazard Ratio (HR)= 1.82), but even higher for COPD (HR= 2.12) after adjusting for age, sex and tobacco exposure.

In a study of 65 patients with ACO, defined as COPD plus a positive bronchodilator test, versus 65 patients with COPD and a negative bronchodilator test, Bai et al⁷³ reported a significantly lower mortality in ACO patients compared to COPD. However, this difference may at least partly be explained by ACO patients having a more preserved diffusion capacity compared to COPD only (DLCO 71% predicted vs 56% predicted, p<0.001). Similarly, Suzuki et al⁷⁴ in the Hokkaido cohort demonstrated a significantly reduced 10-year mortality in patients with COPD who had at least two of the so-called asthma-like features (positive bronchodilator test, increased blood eosinophils and/or atopy), compared with COPD patients with 0 or 1 of these features.

The reported findings from the majority of cohort studies suggest that the risk of death of ACO patients is significantly reduced compared with COPD, but not compared with asthma. This may be due to the different characteristics of ACO patients such as less severe emphysema, but also due to better response to some widely used pharmacological therapies, not least inhaled corticosteroids.

Treatment of ACO

Very few clinical trials have evaluated the efficacy of therapy in ACO; generally, these patients are excluded from clinical trials of COPD or asthma; furthermore, there is a lack of regulatory definition of ACO. Yet, patients with ACO that would possibly benefit from these treatments are encountered frequently in clinical practice. Currently, decisions regarding therapy in these patients should be guided based on phenotypical data and severity of symptoms, taking into account whether asthma or COPD is most pronounced in the individual ACO patient, even in mild stages of the disease.⁷⁵ Next, a stepwise approach similar to the algorithms for the treatment of asthma or COPD must be followed according to the severity of symptoms (Figure 2).^8,21 For patients with milder forms of asthma inhaled therapy comprising of ICS is adequate, while symptomatic COPD patients are treated with long-acting bronchodilators. Yet, there is a key difference; the treatment algorithms recommend that ICS should be introduced earlier in asthma and in COPD patients with a history of exacerbations and/or increased blood eosinophils.^8,21 ICS improves asthma outcomes with regard to exacerbations, control of symptoms and lung function.^76,77 Importantly, long-acting beta-2 agonists (LABA) have been associated with an increased risk of asthma-related death when not given in combination with an ICS and should not be prescribed as a single therapy in asthma.^78,79 Given this risk, it is recommended that a LABA should always be prescribed in conjunction with ICS in patients with ACO.⁸⁰ Furthermore, studies have shown that in ACO patients the use of ICS/LABA appears to be safe and effective.⁸¹ There is no evidence of the efficacy and safety of the use of PRN ICS/formoterol for relief of symptoms on top of maintenance treatment in ACO patients; however, this appears to be a reasonable option since a long-acting bronchodilator with a quick onset of action may be effective in symptoms control and these patients respond well to ICS. The initiation of a short course of ICS/LABA in patients with COPD at the onset of a lower respiratory tract infection has been shown to reduce the risk of severe exacerbations.⁸² Leukotriene receptor antagonists have not been demonstrated to be effective in COPD; however, they may be used in ACO patients with the phenotype of smoking asthmatic.⁸⁰

Figure 2.

Treatment algorithm for ACO.

Notes: *Due to risk in asthmatics with LABA monotherapy, ICS is the preferred therapy in ACO. **For patients with a chronic bronchitis phenotype and a FEV1 < 50%. ***For ex-smokers and infective exacerbations.

Abbreviations: ACO, asthma COPD overlap; FeNO, exhaled nitric oxide; ICS, inhaled corticosteroids; IgE, immunoglobulin E; IL, interleukin; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist.

The combination of ICS/LABA/long-acting muscarinic antagonist (LAMA) (ie triple therapy) has been effective in asthma by improving lung function and in COPD by reducing exacerbations versus ICS/LABA.^83–89 Therefore, if a patient with ACO is not adequately controlled with a combination of an ICS/LABA, then a LAMA should be considered as an adjunctive therapy, particularly in the setting of recurrent exacerbations. Although small studies have supported the use of triple therapy in ACO, larger, more definitive, studies are still required to confirm the benefit and safety of this strategy in this patient population.⁹⁰

If an ACO patient remains uncontrolled despite maximal inhaler therapy, other treatment options may be considered. Roflumilast is an oral phosphodiesterase 4 inhibitor that is effective in preventing exacerbations in patients with COPD and chronic bronchitis. Some studies have observed that roflumilast may be more effective in COPD patients with high blood eosinophils.⁹¹ On the other hand, roflumilast has been demonstrated to be effective in asthma;^92,93 therefore, it is likely that ACO patients with chronic cough and sputum production may benefit from this treatment for prevention of exacerbations.⁹¹ Another possible treatment is montelukast, with very limited efficacy in COPD, but has demonstrated to improve asthma control in smoking asthmatics.⁹⁴

In patients with moderate-to-severe asthma, monoclonal antibodies that target T2 inflammatory cytokines have been shown to decrease exacerbations and corticosteroid requirements and improve lung function and quality of life.^95–99 These targeted therapies have been studied in COPD with mixed results. A study evaluated the response to omalizumab, a monoclonal antibody that targets immunoglobulin E, in patients with ACO compared to those with asthma alone.¹⁰⁰ Participants were assessed at baseline and after 6 months of therapy and both groups demonstrated improvements in symptom control and quality of life. Another study evaluated the efficacy of omalizumab over 48 weeks of therapy and reported similar improvements in exacerbation rate and symptom control in subjects with ACO or asthma alone.¹⁰¹ Mepolizumab, a monoclonal antibody directed against IL-5, has been tested in two Phase III, placebo-controlled, double-blind, randomized, multinational trials (METREX and METREO) in COPD patients on triple therapy and varying levels of blood eosinophils.¹⁰² Only one of the trials (METREX) reached the primary endpoint of significant reduction of exacerbations after 52 weeks of mepolizumab vs placebo (1.40 vs 1.71 per year; rate ratio 0.82; 95% CI, 0.68–0.98; P=0.04) in patients with an eosinophilic phenotype. There were no improvements in the SGRQ or CAT score in either trial.¹⁰² Finally, the use of benralizumab, an IL-5 receptor alpha-directed cytolytic monoclonal antibody, did not improve the rates of exacerbations in two phase III, randomized, placebo-controlled trials that included patients with moderate to severe COPD with eosinophilic phenotype and a history of exacerbations.¹⁰³ Yet, a subgroup analysis revealed that benralizumab reduced exacerbations in those patients who, on top of an eosinophilic phenotype, also had three or more exacerbations in the past year, impaired lung function (ie post-bronchodilator FEV1 < 40%) and significant bronchodilator response (ie >15%).¹⁰⁴ Altogether, these findings suggest that T2 targeted therapies may be beneficial in a subgroup of patients with COPD, particularly those that have features of asthma. Thus, these therapies should not be withheld in patients with ACO.

Chronic therapy with azithromycin has been shown to reduce exacerbations in both asthma and COPD.^105–108 Careful consideration of risks and benefits is recommended before starting this therapy in chronic airway diseases.^8,21 For ACO patients, chronic therapy with azithromycin may be considered, particularly in those patients that have frequent exacerbations and are not candidates for other therapies.⁸⁰

ACO in Clinical Practice Guidelines

As early as 2007, the Canadian guidelines for COPD recognised that some patients with COPD may have an asthma component and may require different treatments, in particular an early introduction of ICS.⁴ Three years later, in 2010, the Japanese guidelines on COPD included a chapter on “COPD complicated by asthma” which also recommended the early introduction of ICS in these patients.¹⁰⁹ These two documents did not include a precise definition of the overlap between COPD and asthma; they only indicated that characteristics of both diseases may coexist in some patients and that this could have implications for treatment. One of the first national guidelines to introduce the term ACO was the Spanish COPD guidelines in 2012;¹¹⁰ and for the first time, this document included a consensus definition of ACO.¹¹¹ Interestingly, a few years later, the Czech,¹¹² the Finnish,¹¹³ the Middle East-North Africa Region,¹¹⁴ and the latest update of the Japanese COPD guidelines²⁰ adopted the same approach, with few modifications, in their documents.

A crucial time in the acceptance of ACO by the medical community was the publication in 2014 of the joint document by GINA-GOLD. This document presented a list of characteristics that identify COPD or asthma and the coexistence of a similar number of traits for both diseases in an individual patient was suggested as a diagnostic of ACO.⁶

The initial criteria for ACO included a series of clinical and biological variables that were difficult to apply in clinical practice. With the advancing knowledge on the relevant characteristics of this phenotype it was possible to simplify the criteria and the new Spanish consensus included the two main types of patients with ACO: COPD with coexistent asthma and eosinophilic COPD.^16,115 It was recognised that these two types of patients were different, but they were grouped together under the umbrella term of ACO because the therapeutic approach was the same.¹¹⁶ Other guidelines, such as the Portuguese guideline on COPD, have followed a similar approach.¹¹⁷

However, after the publication of the joint GINA-GOLD statement on ACO in 2014, the following updates of the GOLD document did not explicitly include the concept of ACO in their recommendations for management. Moreover, the 2020 update indicates that GOLD will no longer refer to ACO, but GOLD recommends the use of blood eosinophil counts to direct the therapy with ICS in COPD.⁸ In contrast, GINA 2020 refers to ACO or “asthma + COPD” as simple descriptors for patients who have features of both asthma and COPD and emphasises that these terms do not refer to a single disease entity. On the contrary, they include patients with several clinical phenotypes that are likely caused by a range of different underlying mechanisms.¹¹⁸ The use of blood eosinophil counts to guide ICS therapy has been included in the new Canadian,¹¹⁹ Spanish¹²⁰ and Latin American guidelines for COPD¹²¹ and in the European Respiratory Society guidelines for ICS withdrawal.¹²² It appears that the tendency for the future will be to differentiate the phenotype of eosinophilic COPD, based on blood eosinophil counts and leave the concept of ACO for patients who fulfil the diagnostic criteria for both asthma and COPD simultaneously irrespective of blood eosinophil counts.

Conclusions

In conclusion, despite disagreement on the definition and recognition of ACO as a distinct pathophysiological entity,^123,124 most clinicians and scientists agree that the current definitions of asthma and COPD misclassify a subgroup of patients with a different phenotype in terms of clinical presentation and, most importantly, in terms of clinical course. This is important because an appropriate identification of ACO patients may allow better-targeted therapy, and hopefully, improved clinical course, much like is currently done in asthma and COPD. Hence, this subgroup of patients deserves attention in order to be appropriately identified for further mechanistic studies, and to enable individualized management.

Disclosure

Evgeni Mekov has received grants and personal fees from Chiesi, and speaker or consulting fees from Astra Zeneca and Chiesi. Alexa Nuñez is the recipient of a Rio Hortega contract in the 2019 Strategic Action Health Call from the Instituto de Salud Carlos III for the years 2020–2022. Don D. Sin has received honoraria for speaking engagements on COPD topics from AstraZeneca, Boehringer Ingelheim and has sat on advisory boards of AZ, Grifols and Nuvaira. Masakazu Ichinose has received honoraria for speaking from AstraZeneca, Nippon Boehringer Ingelheim, Kyorin and Novartis Pharma. Chin Kook Rhee reports personal fees from MSD and consulting/lecture fees from AstraZeneca, GSK, Novartis, Takeda, Mundipharma, Boehringer-Ingelheim, Teva, Sanofi, and Bayer, outside the submitted work. Diego Jose Maselli reports personal fees from GlaxoSmithKline, AstraZeneca and Sanofi Regeneron GSK, Genentech, and Sunovion, during the conduct of the study. Andréanne Coté reports grants from GlaxoSmithKline personal fees from Sanofi Regeneron, and consulting and speaker fees on asthma topics from AstraZeneca, GlaxoSmithKline and Sanofi. Charlotte Suppli Ulrik has received speaker fees and/or research grants from AstraZeneca, GSK, Boehringer-Ingelheim, Chiesi, TEVA, Mundipharma, Sandoz, Actelion, Orion Pharma, Novartis, Sanofi Genzyme and ALK-Abello and has been on advisory boards for AstraZeneca, GSK, Boehringer-Ingelheim, Chiesi, Novartis, Sanofi Genzyme and TEVA. Francois Maltais reports grants from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, GSK, Sanofi, Grifols, and Novartis, and personal fees for serving on speaker bureaus and consultation panels from GlaxoSmithKline, Boehringer Ingelheim, Grifols, and Novartis; he is financially involved with Oxynov, a company which is developing an oxygen delivery system. Antonio Anzueto has received consultant fees from AstraZeneca, Boehringer Ingelheim, Grifols; GlaxoSmithKline, Verona Pharma, TEVA, Mylan/Theravance. Marc Miravitlles has received speaker/personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, Sandoz, Zambon, CSL Behring, Grifols and Novartis, consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, Kamada, CSL Behring, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, TEVA, Spin Therapeutics, pH Pharma, Novartis, Sanofi and Grifols and research grants from Grifols. The authors reported no other potential conflicts of interest for this work.